Role of T. cruzi exposure in the pattern of T cell cytokines among chronically infected HIV and Chagas disease patients

Imagem de Miniatura
Citações na Scopus
Tipo de produção
Data de publicação
Título da Revista
ISSN da Revista
Título do Volume
CLINICS, v.72, n.11, p.652-660, 2017
Projetos de Pesquisa
Unidades Organizacionais
OBJECTIVES: The impact of Chagas disease (CD) in HIV-infected patients is relevant throughout the world. In fact, the characterization of the adaptive immune response in the context of co-infection is important for predicting the need for interventions in areas in which HIV and Chagas disease co-exist. METHODS: We described and compared the frequency of cytokine-producing T cells stimulated with soluble antigen of Trypanosoma cruzi (T. cruzi) using a cytometric assay for the following groups: individuals with chronic Chagas disease (CHR, n=10), those with Chagas disease and HIV infection (CO, n=11), those with only HIV (HIV, n=14) and healthy individuals (C, n=15). RESULTS: We found 1) a constitutively lower frequency of IL-2+ and IFN-gamma+T cells in the CHR group compared with the HIV, CO and healthy groups; 2) a suppressive activity of soluble T. cruzi antigen, which down-regulated IL-2+CD4+ and IFN-gamma+ CD4+ phenotypes, notably in the healthy group; 3) a down-regulation of inflammatory cytokines on CD8+ T cells in the indeterminate form of Chagas disease; and 4) a significant increase in IL-10 + CD8+ cells distinguishing the indeterminate form from the cardiac/digestive form of Chagas disease, even in the presence of HIV infection. CONCLUSIONS: Taken together, our data suggest the presence of an immunoregulatory response in chronic Chagas disease, which seems to be driven by T. cruzi antigens. Our findings provide new insights into immunotherapeutic strategies for people living with HIV/AIDS and Chagas disease.
Intracellular Cytokines, Chagas Disease, HIV, Trypomastigote Antigen, T Cells
  1. Almeida EA, 2010, T ROY SOC TROP MED H, V104, P447, DOI 10.1016/j.trstmh.2010.02.004
  2. Altclas J, 2005, BONE MARROW TRANSPL, V36, P123, DOI 10.1038/sj.bmt.1705006
  3. Bailer RT, 1999, J IMMUNOL, V162, P7534
  4. BRITTO C, 1993, MEM I OSWALDO CRUZ, V88, P171, DOI 10.1590/S0074-02761993000100030
  5. Brockman MA, 2009, BLOOD, V114, P346, DOI 10.1182/blood-2008-12-191296
  6. Bui CT, 2015, CLIN VACCINE IMMUNOL, V22, P193, DOI 10.1128/CVI.00514-14
  7. Campos SV, 2008, J HEART LUNG TRANSPL, V27, P597, DOI 10.1016/j.healun.2008.02.017
  8. Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771
  9. de Almeida EA, 2011, REV SOC BRAS MED TRO, V44, P762, DOI 10.1590/S0037-86822011000600021
  10. de Araujo FF, 2012, IMMUNOBIOLOGY, V217, P768, DOI 10.1016/j.imbio.2012.04.008
  11. de Barros-Mazon S, 2004, CLIN IMMUNOL, V111, P137, DOI 10.1016/j.clim.2004.01.002
  12. de Melo AS, 2012, CYTOKINE, V58, P207, DOI 10.1016/j.cyto.2012.01.008
  13. Dutra WO, 2008, CURR OPIN INFECT DIS, V21, P287, DOI 10.1097/QCO.0b013e3282f88b80
  14. Garcia MN, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003981
  15. Garcia-Knight MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143043
  16. GRANT IH, 1989, ANN INTERN MED, V111, P849, DOI 10.7326/0003-4819-111-10-849
  17. Jensen K, 2016, CLIN VACCINE IMMUNOL, V24
  18. KIRCHHOFF LV, 1987, AM J MED, V82, P915, DOI 10.1016/0002-9343(87)90152-5
  19. Kwon DS, 2012, J VIROL, V86, P6586, DOI 10.1128/JVI.06251-11
  20. Laucella SA, 2004, J INFECT DIS, V189, P909, DOI 10.1086/381682
  21. Luz Z M, 1994, Rev Soc Bras Med Trop, V27, P143
  22. Machado FS, 2012, SEMIN IMMUNOPATHOL, V34, P753, DOI 10.1007/s00281-012-0351-7
  23. MAGGI E, 1994, SCIENCE, V265, P244, DOI 10.1126/science.8023142
  24. Milagres LG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115887
  25. Milagres LG, 2013, AIDS, V27, P2697, DOI 10.1097/QAD.0000000000000007
  26. MOSCA W, 1991, MEM I OSWALDO CRUZ, V86, P147, DOI 10.1590/S0074-02761991000200002
  27. O'Neil-Andersen NJ, 2002, CLIN DIAGN LAB IMMUN, V9, P243, DOI 10.1128/CDLI.9.2.243-250.2002
  28. Pereira J. B., 1989, Revista da Sociedade Brasileira de Medicina Tropical, V22, P39
  29. Dias JCP, 2016, REV SOC BRAS MED TRO, V49, P3, DOI 10.1590/0037-8682-0505-2016
  30. Riarte A, 1999, CLIN INFECT DIS, V29, P561, DOI 10.1086/598634
  31. Rodrigues DBR, 2005, REV SOC BRAS MED TRO, V38, P483, DOI 10.1590/S0037-86822005000600007
  32. Sartori AMC, 2007, ANN TROP MED PARASIT, V101, P31, DOI 10.1179/136485907X154629
  33. SARTORI AMC, 1995, CLIN INFECT DIS, V21, P1297, DOI 10.1093/clinids/21.5.1297
  34. Schmunis GA, 2001, AM J TROP MED HYG, V65, P924, DOI 10.4269/ajtmh.2001.65.924
  35. Schmunis GA, 2010, ACTA TROP, V115, P14, DOI 10.1016/j.actatropica.2009.11.003
  36. Sousa AE, 1998, CLIN EXP IMMUNOL, V112, P294
  37. Sun L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155420
  38. de Freitas VLT, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001277
  39. Umezawa ES, 2001, LANCET, V357, P797, DOI 10.1016/S0140-6736(00)04174-X
  40. VANVOORHIS WC, 1992, J IMMUNOL, V148, P239
  41. World Health Organization (WHO), 2015, CHAG DIS AM TRYP
  42. World Health Organization, 2016, GLOB AIDS